USE OF DE-NOVO mTOR INHIBITORS IN HYPERSENSITZED KIDNEY TRASPLANT RECIPIENTS: EXPERIENCE FROM CLINICAL PRACTICE.

BACKGROUND It is commonly believed that mTOR inhibitors (mTORi) should not be used in high-immunological risk kidney transplant recipients, due to a perceived increased risk of rejection. However, almost all trials that examined the association of optimal-dose mTORi with Calcineurin Inhibitor (CNI) have excluded hypersensitized recipients from enrollment. METHODS To shed light on this issue, we examined 71 consecutive patients with a baseline cPRA ≥ 50% that underwent kidney transplantation from June 2013 to December 2016 in our Unit. Immunosuppression was based on CNI (tacrolimus), steroids and alternatively Mycophenolic Acid (MPA, n=38) or mTORi (either everolimus or sirolimus, n=33, target trough levels 3-8 ng/ml). RESULTS Demographic and immunological risk profiles were similar and almost 90% of patients in both groups received induction with lymphocyte-depleting agents. Cox-regression analysis of rejection-free survival revealed better results for mTORi versus MPA in terms of biopsy-proven acute rejection [Hazard Ratio (HR)(Confidence Interval) 0.32 (0.11-0.90), P=0.031 at univariable analysis, and 0.34 (0.11-0.95), P=0.040 at multivariable analysis]. There were no differences in 1-year renal function, Banff chronicity score at 3- and 12-month protocol biopsy and development of de-novo DSAs. Tacrolimus trough levels along the first year were not different between groups (12-month levels were 8.72 ± 2.93 and 7.85 ± 3.07 ng/ml for MPA and mTORi group respectively, P=0.277). CONCLUSIONS This single-center retrospective cohort analysis suggests that in hypersensitized kidney transplant recipients receiving tacrolimus-based immunosuppressive therapy similar clinical outcomes may be obtained using mTOR inhibitors compared to mycophenolate.

[1]  S. Chadban,et al.  Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. , 2018, Journal of the American Society of Nephrology : JASN.

[2]  J. Rovira,et al.  Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection , 2018, Transplantation.

[3]  F. Diekmann,et al.  Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome , 2018, Kidney international reports.

[4]  M. Stegall,et al.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  J. Pascual,et al.  Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[6]  F. Luan,et al.  Efficacy and Safety of Everolimus Plus Low‐Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard‐Dose Tacrolimus in De Novo Renal Transplant Recipients: 12‐Month Data , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  OPTN/SRTR 2015 Annual Data Report: Preface , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  J. Rovira,et al.  Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro. , 2016, Transplantation proceedings.

[9]  Mary E. Ziegler,et al.  Everolimus Inhibits Anti‐HLA I Antibody‐Mediated Endothelial Cell Signaling, Migration and Proliferation More Potently Than Sirolimus , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  S. Takahara,et al.  Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results , 2013, Transplantation research.

[11]  R. Walker,et al.  Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation , 2013, Transplantation.

[12]  K. Budde,et al.  Combined standard and novel immunosuppressive substances affect B-lymphocyte function. , 2013, International immunopharmacology.

[13]  N. Unterwalder,et al.  Effects of sotrastaurin, mycophenolic acid and everolimus on human B‐lymphocyte function and activation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[14]  M. Christiaans,et al.  Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  E. Wang,et al.  Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[16]  A. Matas,et al.  Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  L. Kucirka,et al.  Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.

[18]  Sandra K. Wittmann,et al.  Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  D. Roelen,et al.  Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin , 2008, Transplantation.

[20]  W. Meyers,et al.  Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. , 2008, Transplant immunology.

[21]  S. Jordan,et al.  Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.

[22]  L. Shaw,et al.  Multicenter, Randomized Study of the Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates its Effectiveness , 2008, Transplantation.

[23]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[24]  M. Franco,et al.  Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus‐based immunosuppressive regimen , 2007, Clinical transplantation.

[25]  G. Opelz,et al.  Disassociation Between Risk of Graft Loss and Risk of Non-Hodgkin Lymphoma With Induction Agents in Renal Transplant Recipients , 2006, Transplantation.

[26]  D. Abramowicz,et al.  Tacrolimus Combined with Two Different Dosages of Sirolimus in Kidney Transplantation: Results of a Multicenter Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  S. Jensik,et al.  A Prospective, Randomized Trial of Tacrolimus in Combination with Sirolimus or Mycophenolate Mofetil in Kidney Transplantation: Results at 1 Year , 2005, Transplantation.

[28]  S. Mulgaonkar,et al.  Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study , 2005, Transplantation.

[29]  Raimund Margreiter,et al.  Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients , 2004, Transplantation.

[30]  J. Gaynor,et al.  A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year , 2004, Transplantation.

[31]  O. Toupance,et al.  Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF‐containing Triple Therapy , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  D. Jelinek,et al.  Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. , 1994, Cellular immunology.